bs-12949R [Primary Antibody]
CRTAP Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: CRTAP

Immunogen Range: 201-300/401

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 10491

Source: KLH conjugated synthetic peptide derived from human CRTAP

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide.

Storage Condition: Store at -20°C for 12 months..

Background: CRTAP is a secreted protein localizing to the extracellular space that plays a role in collagen post-translational modifications, extracellular fibril assembly and intracellular trafficking. CRTAP is widely expressed with predominant expression in articular chondrocytes. It contains a signal peptide and a tetratricopeptide-like helical domain and is essential for normal bone formation. In the endoplasmic reticulum (ER), CRTAP forms a complex with Gros1 and CyPB (cyclophilin B) and is required for the efficient 3-hydroxylation of target prolyl residues in Collagen Type I molecules, the major structural proteins of skin and bone. Mutations in the gene encoding CRTAP can lead to autosomal recessive osteogenesis imperfecta (OI) type 7 and type 2B. OI, also known as brittle bone disease, is characterized by bone fragility and susceptibility to fractures. OI type 7 is a mild form of this disorder, while OI type 2B is a neonatal lethal condition.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-1000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)
ICC(1:100-500)

Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Dog
Pig
Horse
Chicken
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: U251 cell lysates;Lane 2: A549 cell lysates probed with CRTAP Polyclonal Antibody, Unconjugated (bs-12949R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.